Weight-of-evidence assessment of the endocrine-disrupting properties of propylene oxide

. Similarly, adverse outcomes observed in repeated-dose, reproductive, and developmental toxicity studies were either secondary to systemic toxicity, inconsistent, or unrelated to endocrine modes of action. Epidemiological findings suggesting associations with breast cancer, diabetes, or obesity were limited by methodological uncertainties and lack of causal inference. Collectively, the WoE demonstrates that PO should not be classified as an endocrine-disrupting chemical for humans or wildlife, although data gaps remain for environmental receptors and metabolites.